About Us

iTolerance is a privately held biotechnology company advancing a localized immune tolerance platform designed to enable durable engraftment of transplanted cells, tissues and organoids without the need for lifelong systemic immunosuppression. Its proprietary iTOL-100 platform uses localized Treg modulation to reduce immune attack and support long-term graft survival and function. The platform has demonstrated compelling results across multiple preclinical studies.

The Company’s lead program, iTOL-101, combines iTOL-100 with allogeneic cadaveric pancreatic islets for the treatment of Type 1 Diabetes. In a nonhuman primate study, iTOL-101 demonstrated long-term islet graft survival, glycemic control and reduced reliance on insulin. The Company is advancing iTOL-101 toward a Phase 1/2a investigator-initiated trial at Shanghai Changzheng Hospital, a world-class islet and organ transplant institute. iTolerance is also developing iTOL-102, which combines iTOL-100 with stem cell-derived pancreatic islets, and plans to expand the platform into additional organ systems.

Our Values